Edition:
United Kingdom

People: Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.31USD
13 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.31
Open
$0.31
Day's High
$0.31
Day's Low
$0.29
Volume
373,427
Avg. Vol
146,692
52-wk High
$14.55
52-wk Low
$0.26

Sidransky, David 

Dr. David Sidransky, M.D., is Independent chairman of the Board of the Company. He is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and Ayala and serves on the Board of Directors of Galmed and Orgenesis. He has served on scientific advisory boards of MedImmune, Roche, Amgen, and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).

Basic Compensation

Total Annual Compensation, USD 301,750
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,719,050
Fiscal Year Total, USD 2,020,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Sidransky

2,020,800

Kenneth Berlin

1,797,460

James Patton

--

Molly Henderson

521,871

Roni Appel

144,615

Samir Khleif

--
As Of  31 Oct 2018